Rocket Pharmaceuticals (RCKT) Other Non-Current Assets (2014 - 2026)

Rocket Pharmaceuticals has reported Other Non-Current Assets for 13 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 1.54% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 1.54% YoY) and the FY2025 annual result came in at $482000.0, down 8.88% from the prior year.
• Other Non-Current Assets rose to $1.3 million in Q1 2026 per RCKT's latest filing, from $482000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $1.4 million in Q2 2025 and troughed at $455000.0 in Q1 2022.
• A 5-year average of $1.0 million and a median of $1.3 million in 2022 frame the typical range for Other Non-Current Assets.
• The widest YoY moves for Other Non-Current Assets: up 195.16% in 2022, down 68.86% in 2022.
• Over 5 years, Other Non-Current Assets stood at $1.3 million in 2022, then sank by 60.22% to $533000.0 in 2023, then declined by 0.75% to $529000.0 in 2024, then fell by 8.88% to $482000.0 in 2025, then jumped by 178.22% to $1.3 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.3 million, $482000.0, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.